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Aberrant ETB receptor regulation of AT1 receptors in immor-
talized renal proximal tubule cells of spontaneously hyperten-
sive rats.
Background. The renin-angiotensin and endothelin systems
interact to regulate blood pressure, in part, by affecting sodium
transport in the kidney. Because angiotensin II type 1 (AT1)
receptor activation increases ETB receptor expression in renal
proximal tubule cells from Wistar-Kyoto (WKY) rat, we hy-
pothesize that ETB receptor activation may also regulate AT1
receptor expression. Furthermore, ETB receptor regulation of
the AT1 receptor may be different in the WKY and sponta-
neously hypertensive rat (SHR).
Method. AT1 and ETB receptors were studied in immortal-
ized renal proximal tubule cells from WKY and SHRs, using
immunoblotting, confocal microscopic colocalization, and im-
munoprecipitation.
Results. In WKY renal proximal tubule cells, an ETB receptor
agonist, BQ3020, decreased AT1 receptor protein in a time- and
concentration-dependent manner [median effective concentra-
tion (EC50) = 3.2 × 10−10 mol/L, t1/2 = 15 hours]. The inhibitory
effect of BQ3020 (10−8 mol/L/24 hours) on AT1 receptor protein
was blocked by an ETB receptor antagonist (BQ788). However,
BQ3020 (10−8 mol/L/24 hours) increased ETB receptor protein
in WKY renal proximal tubule cells. In contrast, in SHR re-
nal proximal tubule cells, BQ3020 (10−8 mol/L/24 hours) no
longer affected AT1 or ETB receptor protein. AT1/ETB recep-
tors colocalized and coimmunoprecipitated in WKY and SHRs.
BQ3020 (10−8 mol/L/15 minutes) treatment had no effect on
AT1/ETB coimmunoprecipitation in WKY but decreased it in
SHRs. BQ3020 (10−8 mol/L/15 minutes) treatment increased
AT1 receptor phosphorylation in WKY, but decreased it in
SHRs.
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Conclusion. ETB receptors regulate AT1 receptors by direct
physical receptor interaction and receptor expression. An im-
paired ETB receptor regulation of the AT1 receptor may par-
ticipate in the pathogenesis of high blood pressure in the SHR.
Enhanced sodium transport in the renal proximal
tubule and thick ascending limb of Henle occurs in hu-
man essential and rodent genetic hypertension [1–3]. This
enhanced sodium transport may be caused by increased
activity of antinatriuretic agents and/or decreased activity
of natriuretic agents [4–9].
The renin-angiotensin system plays a critical role in the
regulation of blood pressure and renal excretory function
[7–9]. Angiotensin II is functionally the most relevant
peptide of this system, and its antinatriuretic and prohy-
pertensive actions are mediated by the activation of the
angiotensin II type 1 (AT1) receptor [6–9].
Endothelins are a family of three isopeptides (ET1,
ET2, and ET3), for which at least two types of recep-
tors have been identified (ETA and ETB) [10, 11]. Renal
proximal tubules express AT1, ETA, and ETB receptors
[7–11]. Several studies have shown that the ETA recep-
tor decreases while the ETB receptor increases sodium
excretion [12–17]. The interplay between the natriuretic
ETB/antinatriuretic ETA and AT1 receptors represents
one pathway in the regulation of renal sodium and water
excretion [18–20].
The renin-angiotensin system may exert some of its
effects via an interaction with the endothelin system [18–
20]. Angiotensin II regulates endothelin synthesis in the
kidney [19]. Endothelin has multifaceted effects on the
renin-angiotensin-aldosterone system, such as a dose-
dependent inhibition of renin production and direct stim-
ulation of aldosterone and promotion of growth of the
adrenal cortex [18–21].
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In a preliminary communication, we showed that AT1
and ETB receptors colocalize and coimmunoprecipitate
in renal proximal tubule cells, and stimulation of the AT1
receptor increases ETB receptor expression in Wistar-
Kyoto (WKY) rats [abstract; Zeng C, et al, Hypertension
26:80A, 2003]. We hypothesize that the ETB receptor
may also regulate the AT1 receptor, including its expres-
sion. In the current study we examined the interaction
between AT1 and ETB receptors in immortalized rat
renal proximal tubule cells, which have characteristics
similar to freshly obtained renal proximal tubule brush
border membranes and renal proximal tubules, at least
with regard to D1 receptors and their responses to G
protein stimulation [22–25]. We now report that long-
term activation of the ETB receptor decreases AT1 re-
ceptor and increases ETB receptor expression in renal
proximal tubule cells from WKY rats. In contrast, in the
spontaneously hypertensive rat (SHR), the ETB recep-
tor has no effect on AT1 receptor expression. ETB recep-
tor activation does not influence AT1 and ETB receptor
coimmunoprecipitation in WKY cells, but decreases it
in SHR cells. Short-term treatment with the ETB ago-
nist, BQ3020, increases phosphorylation of the AT1 re-
ceptor in WKY cells, but decreases it in SHR cells. We
conclude that ETB receptors regulate AT1 receptors by
direct physical receptor interaction and receptor expres-
sion. The role of ETB regulation of AT1 receptor expres-
sion and phosphorylation on renal proximal tubule ion
transport, however, remains to be determined.
METHODS
Cell culture
Immortalized renal proximal tubule cells from 4- to 8-
week-old SHR and WKY rats were cultured at 37◦C in
95% air/5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 culture media, as previously described
[abstract; Zeng C, et al, Hypertension 26:80A, 2003] [22,
25–27]. The cells (80% confluence) were extracted in ice-
cold lysis buffer [phosphate-buffered saline (PBS) with
1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 1 mmol/L ethylenediaminete-
traacetic acid (EDTA), 1 mmol/L ethyleneglycol tetraac-
etate (EGTA), 1 mmol/L phenylmethylsulfonyl fluoride
(PMSF), 10 lg/mL aprotinin, and 10 lg/mL leupeptin),
sonicated, placed on ice for 1 hour, and centrifuged at
16,000g for 30 minutes. The supernatants were stored at
−70◦C until use for immunoblotting and/or immunopre-
cipitation.
Immunoblotting
The amino acid sequence of the AT1 receptor immuno-
genic peptide (rabbit antihuman AT1 receptor antibody)
(Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA)
is QDDCPKAGRHC (amino acids 15 to 24) [22, 27].
The amino acid sequence of the ETB receptor immuno-
genic peptide (rabbit antirat ETB receptor antibody)
(Alomone Labs, Jerusalem, Israel) is CEMLRKKSG-
MQIALND (amino acids 298 to 314) [28]. The speci-
ficities of these antibodies have been reported [22, 27,
28]. Renal proximal tubule cells were treated with vehi-
cle (dH2O), an ETB agonist (BQ3020) [29, 30] (Sigma
Chemical Co., St. Louis, MO, USA), and/or an ETB
receptor antagonist (BQ788) [29, 30] (Sigma Chemical
Co.), at the indicated concentrations and times. BQ3020
is 1000-fold selective to the ETB receptor relative to the
ETA receptor in human kidney and other tissues [31–33].
Immunoblotting was performed as reported [22–27], ex-
cept that the transblots were probed with ETB (1:300) or
AT1 receptor antibodies (1:400).
Confocal microscopy of doubly stained renal proximal
tubule cells
Renal proximal tubule cells grown on coverslips were
fixed and permeabilized with 100% methanol (for 30 min-
utes) [34, 35]. The ETB receptor was visualized by a
rabbit antirat ETB receptor antibody followed by a fluo-
rescein isothiocyanate (FITC)-conjugated antirabbit sec-
ondary antibody (Molecular Probes, Eugene, OR, USA).
The AT1 receptor was visualized by a mouse anti-AT1
receptor monoclonal antibody (Abcam Limited, Cam-
bridgeshire, UK), followed by an Alexa Fluor 568-goat
antimouse IgG antibody (Molecular Probes). Cells on
coverslips were mounted with the ProLong Antifade Kit
(Molecular Probes). Negative controls included absence
of the primary or the secondary antibodies, or antibodies
preadsorbed with the immunizing peptide (1:10 wt/wt).
The immunofluorescence densities and images were ac-
quired (Olympus AX70) at an excitation wavelength of
488 nm and 568 nm; emission was detected at 535 and
645 nm.
Immunoprecipitation
Renal proximal tubule cells were incubated with vehi-
cle (dH2O) or BQ3020 (10−8 mol/L) for 15 minutes, as
described above. The cells were lysed with ice-cold lysis
buffer for 1 hour and centrifuged at 16,000g for 30 min-
utes. Equal amounts of lysates (500 lg protein/mL super-
natant for renal proximal tubule cells from WKY rats and
SHRs) were incubated with affinity-purified anti-ETB
receptor antibody (for AT1/ETB receptor coimmuno-
precipitation) or polyclonal antiphosphoserine antibody
(Zymed Laboratory, South San Francisco, CA, USA) (for
AT1 receptor phosphorylation) (1 lg/mL) for 1 hour and
protein G agarose at 4◦C for 12 hours. The immunopre-
cipitates were pelleted and washed four times with ly-
sis buffer. The pellets were suspended in sample buffer,
boiled for 10 minutes, and subjected to immunoblotting
with the AT1 receptor. In order to determine the speci-
ficity of the bands, normal rabbit IgG (negative control)
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and AT1 receptor antibody (positive control) were used
as immunoprecipitants. The density of the bands were
semiquantified by densitometry using Quantiscan (Fer-
guson, MO, USA), as previously reported [22–27].
Statistical analysis
The data are expressed as mean ± SEM. Comparison
within groups was made by repeated-measures analysis of
variance (ANOVA) and comparison among groups was
made by factorial ANOVA and Holm-Sidak test. A value
of P < 0.05 was considered significant.
RESULTS
ETB receptors decrease AT1 receptor expression in renal
proximal tubule cells from WKY rats, but not from SHRs
An ETB receptor agonist, BQ3020, decreased AT1
receptor expression in a concentration- and time-
dependent manner in renal proximal tubule cells from
WKY rats. The inhibitory effect was evident at 10−10
mol/L with a 50% decrease [median effective concen-
tration (EC50)] at 3.2 × 10−10 mol/L (Fig. 1A). The in-
hibitory effect of BQ3020 (10−8 mol/L) was noted as early
as 2 hours and maintained for at least 30 hours; a 50%
decrease (t1/2) in AT1 receptor expression occurred at
15 hours (Fig. 1B). In renal proximal tubule cells from
SHRs, BQ3020 had no effect on AT1 receptor expres-
sion [SHR control = 1.08 ± 0.08, BQ3020 (10−8 mol/L/24
hours) = 1.04 ± 0.12] (N = 15) [WKY control = 1.12 ±
0.12, BQ3020 (10−8 mol/L/24 hours) = 0.76 ± 0.08] (N =
15) (Fig. 1C).
To determine whether higher concentrations of
BQ3020 could have an effect on AT1 receptor expres-
sion, SHR cells were treated with varying concentrations
of BQ3020 for 24 hours. Consistent with the results from
Figure 1C, 10−11 to 10−7M BQ3020 had no effect on AT1
receptor protein expression (Fig. 1D).
The specificity of BQ3020 as an ETB receptor agonist
was also determined by studying the effect of the ETB
receptor antagonist, BQ788. Consistent with the studies
shown in Figure 1A to C, BQ3020 (10−8 mol/L/24 hours)
decreased AT1 receptor expression (control = 1.08 ±
0.04, BQ3020 = 0.76 ± 0.04) (N = 7) (P < 0.05). The
ETB receptor antagonist, BQ788 (10−8 mol/L), by itself,
had no effect on AT1 receptor expression (1.08 ± 0.08),
but reversed the inhibitory effect of BQ3020 on ETB re-
ceptor expression (1.09 ± 0.06) (Fig. 1E).
BQ3020 increases ETB receptor expression in renal prox-
imal tubule cells from WKY rats, but not from SHRs
To investigate the effect of BQ3020 on ETB receptors,
renal proximal tubule cells were incubated with BQ3020
(10−8 mol/L/24 hours) at the indicated times and concen-
trations. BQ3020 increased ETB receptor expression in
renal proximal tubule cells from WKY rats (control =
0.92 ± 0.12, BQ3020 = 1.24 ± 0.12) (P < 0.05) (N = 11).
However, there was no effect in SHR cells (control = 1.00
± 0.08, BQ3020 = 0.88 ± 0.16) (N = 11) (Fig. 2).
ETB receptor colocalizes and coimmunoprecipitates with
the AT1 receptor in rat renal proximal tubule cells
In order to determine the potential for a direct or an
indirect interaction between ETB and AT1 receptors, we
studied the colocalization of ETB and AT1 receptors in
renal proximal tubule cells from WKY rats by confocal
microscopy. Both ETB and AT1 receptors were found
throughout the cell with evidence of colocalization, espe-
cially at the cell surface membrane (Fig. 3).
To determine whether there is a physical interaction
between the ETB and the AT1 receptor, additional ex-
periments were performed. ETB receptors were first im-
munoprecipitated with anti-ETB receptor antibodies and
then probed with anti-AT1 receptor antibodies. As shown
in Figure 4, the 45 kD band representing the coimmuno-
precipitated ETB and AT1 receptors was not changed by
a 15-minute treatment of BQ3020 (10−8 mol/L) in renal
proximal tubule cells from WKY rats [control = 27 ±
2 density units (DU), BQ3020 = 28 ± 1 DU] (N =
8). However, BQ3020 decreased ETB and AT1 recep-
tor coimmunoprecipitation in SHR cells (control = 28 ±
1 DU, BQ3020 = 17 ± 2 DU) (N = 8) (P < 0.05).
BQ3020 increases AT1 receptor phosphorylation
in WKY cells, but decreases it in SHR cells
The AT1 receptor has cytoplasmic carboxyl-terminal
tail domains that are rich in serine and threonine residues;
phosphorylation of these residues impairs AT1 recep-
tor function [36]. To investigate the effect of BQ3020
on AT1 receptor phosphorylation, renal proximal tubule
cells were treated for 15 minutes. As shown in Figure 5,
BQ3020 increased AT1 receptor phosphorylation in
WKY cells, but decreased it in SHR cells (WKY control =
23 ± 3 DU, BQ3020 = 34 ± 2 DU; SHR control = 26 ±
3 DU, BQ3020 = 17 ± 2 DU) (N = 9) (P < 0.05).
DISCUSSION
The renin-angiotensin-aldosterone system and the en-
dothelin system are two important systems that regulate
blood pressure and renal sodium excretion. Recent stud-
ies indicate that angiotensin II may exert some of its ef-
fects via an interaction with the endothelin system. Thus,
angiotensin II has been reported to increase endothelin-1
synthesis in the kidney [19] and expression of endothelin-
converting enzyme-1 in human umbilical vein endothelial
cells [37]. The hypertrophic and mitogenic effects of an-
giotensin II may also be augmented by endothelin, via
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Fig. 2. Differential effects of BQ3020 (10−8 mol/L/24 hours) on ETB
receptor expression in renal proximal tubule cells from Wistar-Kyoto
(WKY) rats and spontaneously hypertensive rats (SHRs). The cells
were incubated with the indicated time and concentration. Results are
expressed as the ratio of angiotensin II type 1 (AT1) receptor and a-
actin densities (N = 11). ∗P < 0.05 vs. control, ANOVA, Holm-Sidak
test.
ETA receptors [38]. Endothelin, via ETA receptors, may
also act as an amplifier of the vasoconstrictor effect of
angiotensin [39]. There is reciprocal regulation between
the two systems. Endothelin-1 has been reported to de-
crease renin secretion [21]. Endothelin may regulate not
only the hemodynamic effects of angiotensin II but also
the pathologic consequences of increased activity of the
renin-angiotensin-aldosterone system. For example, the
hypertension associated with chronic angiotensin II infu-
sion can be attenuated by an ETA/ETB receptor antago-
nist [19, 20]. In a canine model of Page (kidney wrapping)
hypertension, bosentan, a combined ETA and ETB re-
ceptor antagonist, exerts a hypotensive effect in addition
to that caused by the AT1 receptor antagonist losartan
[40]. However, there are no reports on the ability of ETB
receptors to regulate AT1 receptor expression.
Fig. 1. Effect of BQ3020 on angiotensin II type 1 (AT1) receptor expression in renal proximal tubule cells from Wistar-Kyoto (WKY) rats and
spontaneously hypertensive rats (SHRs). (A) Concentration-response of AT1 receptor expression in renal proximal tubule cells from WKY rats
treated with the BQ3020. Immunoreactive AT1 receptor expression was determined after a 24-hour incubation with the indicated concentrations
of BQ3020. Results are expressed as density units (DU) (N = 9). ∗P < 0.05 vs. control, analysis of variance (ANOVA), Holm-Sidak test. (B)
Time-course of AT1 receptor expression in renal proximal tubule cells from WKY rats treated with BQ3020. The cells were incubated for the
indicated times with 10−8 mol/L BQ3020. Results are expressed as DU (N = 10). ∗P < 0.05 vs. control (0 = time), ANOVA, Holm-Sidak test. (C)
Differential effects of BQ3020 (10−8 mol/L/24 hours) on AT1 receptor expression in renal proximal tubule cells from both WKY rats and SHRs.
The cells were incubated with the indicated time and concentration. Results are expressed as the ratio of AT1 receptor and a-actin densities (N =
15). ∗P < 0.05 vs. control, ANOVA, Holm-Sidak test. (D) Concentration-response of AT1 receptor expression in SHR renal proximal tubule cells
treated with the BQ3020. Immunoreactive AT1 receptor expression was determined after a 24-hour incubation with the indicated concentrations
of BQ3020. Results are expressed as DU (N = 6) (P = NS vs. control, ANOVA, Holm-Sidak test). (E) Effect of BQ3020 and an ETB antagonist
(BQ788) on AT1 receptor expression in renal proximal tubule cells from WKY rats. The cells were incubated with the indicated reagents (BQ3020,
10−8 mol/L; BQ788, 10−8 mol/L) for 24 hours. Results are expressed as the ratio of AT1 receptor and a-actin densities (N = 7). ∗P < 0.05 vs. others,
ANOVA, Holm-Sidak test.
We have reported that ETB and AT1 receptors inter-
act in rat renal proximal tubule cells [abstract; Zeng C,
et al, Hypertension 26:80A, 2003]. Our current studies
support our previous report that ETB and AT1 receptors
can regulate each other at the protein and cell biologic
level [abstract; Zeng C, et al, Hypertension 26:80A, 2003].
The interaction among G protein–coupled receptors can
be synergistic, additive, or negative. The regulation may
occur at the physiologic level where one functional effect
antagonizes the other. In the case of the AT1 receptor,
its vasoconstrictor effect can augment the ability of ETA
and ETB to contract vascular smooth muscle cells [41, 42].
The increase in renal tubular sodium transport caused by
AT1 receptors can augment a similar effect of ETA re-
ceptors. However, the ability of ETB receptors to stimu-
late vasodilatory agents from endothelial cells would be
counter regulatory [43–46], as would be the ability of re-
nal tubular ETB receptors to decrease sodium transport
[10–13, 18].
The ETB receptor has been shown to decrease sodium
transport in the renal medullary collecting duct and
medullary thick ascending limb of Henle [10–13, 18].
However, both inhibitory and stimulatory effects of en-
dothelin have been reported in the proximal tubule [16,
47–49]. In the rat, endothelin acutely inhibits fluid and
bicarbonate transport by reducing Na+/K+ adenosine
triphosphatase (ATPase) activity [17]. Short-term stim-
ulation of ETB receptors in opossum kidney cells, a
renal proximal tubular cell line, activates the sodium hy-
drogen exchanger, NHE3 [50]. However, chronic treat-
ment of the same opossum kidney cells by endothelin
has an opposite effect on NHE3 activity [15]. Thus, a 6-
hour exposure of opossum kidney cells to endothelin-1
inhibits NHE3 expression and activity [15]. It is of inter-
est that the ability of an ETB receptor agonist to decrease
AT1 receptor expression also occurs within the same time
frame as the ability of ETB to inhibit NHE3 expression
and activity. Another G protein–coupled receptor, the D3
dopamine receptor has been shown to inhibit NHE3 ac-
tivity in rat renal proximal tubules and immortalized rat
renal proximal tubule cells [51]. We have preliminary data
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ETB AT1 Merge Fig. 3. ETB and angiotensin II type 1 (AT1)
receptor colocalization in renal proximal
tubule cells from Wistar-Kyoto (WKY) rats.
The cells were washed, fixed, and immunos-
tained for ETB and AT1 receptors, as de-
scribed in the Methods section. Colocalization
appears as yellow after merging the images
of fluorescein isothiocyanate (FITC)-labeled
ETB receptor (green) and Alexa 568-labeled
AT1 receptor (red).
showing that the acute (2 hours) natriuretic effect of a D3
receptor agonist, PD128907, can be blocked by an ETB
receptor antagonist, BQ788 [Zeng C, et al, unpublished
data, 2004]. These preliminary results could be taken to
indicate that the ETB receptor can regulate sodium trans-
port in the renal proximal tubule, in vivo, by interacting
with the D3 receptor. These studies provide evidence for
a potential interaction between the ETB and AT1 recep-
tor, in vivo. We now report that short-term (15 minutes)
BQ3020 treatment increases AT1 receptor phosphoryla-
tion in WKY renal proximal tubule cells. The ability of
ETB receptors to decrease AT1 receptor expression and
to increase its phosphorylation [36] would be in keeping
with a counterregulatory effect of ETB receptors on AT1
receptor action on renal tubular sodium transport. The
decrease in AT1 receptor phosphorylation with BQ3020
in SHR renal proximal tubule cells could participate in
the enhanced AT1 receptor-mediated sodium reabsorp-
tion in hypertension. Direct proof of this action needs to
be shown, however.
The mechanism of the decrease in AT1 receptors
caused by ETB receptors was not studied. However, we
find that short-term stimulation of the ETB receptor
increases AT1 receptor phosphorylation in WKY cells;
phosphorylation has been reported to prompt AT1A re-
ceptor desensitization and internalization [36, 52]. The
importance of G protein–coupled receptor kinase (GRK)
in regulating G protein–coupled receptor function, in-
cluding the AT1 and ETB receptors, has been the subject
of several reviews [53–55]. The AT1 receptor is regulated
by casein kinase 1a and GRK2 [54–56]. We have reported
that GRK2, to a lesser extent, and GRK4, to a greater ex-
tent, regulates the D1 dopamine receptor [57]. We have
found that GRK4 serine phosphorylates and inactivates
the D1 dopamine receptor [58]. In a preliminary commu-
nication, we reported that there is a negative counter reg-
ulation of D1 receptor and GRK4 expression [abstract;
Felder RA, et al, Hypertension 42:438, 2003]. GRK4 may
also regulate the ETB receptor because ETB receptor ex-
pression in renal cortex is higher and ETB receptor phos-
phorylation is lower in GRK4 A142V transgenic mice
[Zeng C, et al, unpublished data, 2004]. It is possible that
there is also negative regulation between ETB receptor
and GRK4, and that the ETB receptor may regulate the
AT1 receptor via GRK4.
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Fig. 4. Effect of BQ3020 on the coimmunoprecipitation of angiotensin
II type 1 (AT1) and ETB receptors in rat renal proximal tubule (RPT)
cells. The cells were incubated with BQ3020 (10−8 mol/L) for 15 min-
utes. Thereafter, the samples were immunoprecipitated with anti-ETB
receptor antibodies and immunoblotted with anti-AT1 receptor anti-
bodies. ∗P < 0.05 vs. control (N = 8), analysis of variance (ANOVA),
Holm-Sidak test. One immunoblot (45 kD) is depicted in the inset [lane
1, negative control; lane 2, positive control; lane 3, vehicle-treated re-
nal proximal tubule cell of Wistar-Kyoto (WKY) rats; lane 4, BQ3020-
treated renal proximal tubule cell of WKY rats; lane 5, vehicle-treated
renal proximal tubule cell of spontaneously hypertensive rats (SHRs);
and lane 6, BQ3020-treated renal proximal tubule cell of SHRs]. For
a positive control anti-AT1 antibodies (1 lg/mL) were used as the im-
munoprecipitant; for a negative control, normal rabbit IgG (1 lg/mL)
was used as the immunoprecipitant instead of the anti-ETB antibodies
and immunoblotted with anti-AT1 antibodies as above.
The interaction between ETB and AT1 receptors is rat
strain dependent. Our previous study in renal proximal
tubule cells indicates that long-term activation (hours)
of the AT1 receptor decreases AT1 receptor expression
and increases ETB receptor expression in WKY cells. In
contrast, in SHRs, AT1 receptor activation increases AT1
receptor expression without affecting ETB receptor ex-
pression [abstract; Zeng C, et al, Hypertension 26:80A,
2003]. In this study, we find that long-term activation of
the ETB receptor decreases AT1 receptor expression and
increases ETB receptor in WKY renal proximal tubule
cells but has no effect on either ETB or AT1 expression
in SHRs. We now report that AT1 and ETB receptors
colocalize in WKY renal proximal tubule cells [abstract;
Zeng C, et al, Hypertension 26:80A, 2003]. These two
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Fig. 5. Effect of BQ3020 on angiotensin II type 1 (AT1) receptor phos-
phorylation in renal proximal tubule cells from Wistar-Kyoto (WKY)
rats and spontaneously hypertensive rats (SHRs). The renal proximal
tubule cellular lysate protein was immunoprecipitated with antiphos-
phoserine antibody and immunoblotted with anti-AT1 receptor anti-
body as described in the Methods section. One immunoblot (45 kD)
is depicted in the inset (lane 1, negative control; lane 2, positive con-
trol; lane 3, vehicle-treated renal proximal tubule cell of WKY rats;
lane 4, BQ3020-treated renal proximal tubule cell of WKY rats; lane 5,
vehicle-treated renal proximal tubule cell of SHRs; and lane 6, BQ3020-
treated renal proximal tubule cell of SHRs]. ∗P < 0.05 vs. control (N
= 9), analysis of variance (ANOVA), Holm-Sidak test. For a positive
control anti-AT1 antibodies (1 lg/mL) were used as the immunopre-
cipitant; for a negative control, normal rabbit IgG (1 lg/mL) was used
as the immunoprecipitant instead of the antiphosphoserine antibodies
and immunoblotted with anti-AT1 antibodies as above.
receptors directly interact with each other because they
coimmunoprecipitate and activation of AT1 receptor in-
creases AT1/ETB coimmunoprecipitation in WKY but
not in SHR cells [abstract; Zeng C, et al, Hypertension
26:80A, 2003]. In the current study, ETB receptor activa-
tion does not affect AT1 and ETB receptor coimmuno-
precipitation in WKY but decreases it in SHR cells. We
now also report that short-term (minutes) activation of
ETB receptors increases the serine phosphorylation of
the AT1 receptor in WKY cells, but decreases it in SHR
cells. The decrease in AT1/ETB receptor coimmunopre-
cipitation in renal proximal tubularRPT cells following
ETB receptor agonist stimulation could not have been
caused by the changes in the expression of either ETB
or AT1 receptors, because the duration of stimulation is
too short (15 minutes) to be caused by changes in recep-
tor expression. However, the results in immortalized re-
nal proximal tubule cells need to be confirmed in freshly
isolated renal proximal tubule cells. Whereas the expres-
sion and transduction of the D1 dopamine receptor sig-
nal is similar in freshly isolated and immortalized renal
proximal tubule cells [22–25], this may not be the case
for other G protein–coupled receptors (e.g., D3 recep-
tor [59]). Given this caveat, our studies suggest that the
activation of the ETB receptor results in its modifica-
tion or action on some adapter protein(s) that links AT1
and ETB receptors. Moreover, this interaction is differ-
ent between WKY rats and SHRs. It is possible that the
dissociation of ETB receptors from AT1 receptors after
ETB receptor stimulation allows these receptors to exert
their actions separately. The inability of ETB receptors
to decrease AT1 receptor expression in renal proximal
tubule of SHRs and a failure to decrease ETB/AT1 re-
ceptor heterodimerization could lead to increased AT1
receptor function. The ETB receptor-induced decrease
in the phosphorylation of the AT1 receptor in SHR cells
may also increase AT1 receptor activity [36]. Renal tubu-
lar AT1 receptor action is enhanced in SHRs [7, 60–62].
CONCLUSION
We have demonstrated that ETB receptors negatively
regulate the expression of AT1 receptors in renal proxi-
mal tubule cells from WKY rats but not in SHRs. Short-
term activation of the ETB receptor increases AT1 re-
ceptor phosphorylation in WKY cells but decreases it
in SHR cells. We conclude that ETB receptors regulate
AT1 receptors by direct physical receptor interaction and
receptor expression. The impaired natriuretic effect in
SHRs may, in part, be related to impaired ETB receptor
regulation of AT1 receptors.
Perspectives
This study shows that long-term activation of ETB re-
ceptor decreases AT1 receptor expression while short-
term activation increases AT1 receptor phosphorylation
in WKY renal proximal tubule cells; these effects are not
seen in SHR renal proximal tubule cells. AT1 and ETB
receptors may modulate each other to maintain a normal
salt balance and a normotensive state. The loss of this
counter regulation may be another mechanism for the
sodium retention and the increase in blood pressure in
SHRs.
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